In vitro and in vivo activity of R- and S-praziquantel enantiomers and the main human metabolite trans-4-hydroxypraziquantel against Schistosoma haematobium

Jana Kovač1,2, Mireille Vargas1,2 and Jennifer Keiser1,2*

Abstract

Background: Praziquantel (PZQ) is the mainstay of schistosomiasis control and has been successfully used for decades. However, its mechanism of action is not fully understood. While the majority of studies have been conducted on Schistosoma mansoni, it is not known which enantiomer, R- or S-praziquantel (R-/S-PZQ), is responsible for the activity on Schistosoma haematobium.

Methods: In vitro and in vivo studies were conducted to evaluate the activity of R- and S-PZQ, racemic PZQ and the main human metabolite, namely trans-4-OH-PZQ, on S. haematobium. IC50 values on adult S. haematobium were determined in vitro. Dose-response relationship studies were performed in golden Syrian hamsters, harbouring a chronic S. haematobium infection.

Results: R-PZQ displayed the highest activity against adult worms in vitro, revealing an IC50 of 0.007 μg/ml at 4 h and 0.01 μg/ml at 72 h. In contrast, S-PZQ was 501× less active (eudysmic ratio at 4 h), with an IC50 of 3.51 and 3.40 μg/ml (4 and 72 h, respectively). Racemic PZQ and trans-4-OH-PZQ resulted in an IC50 of 0.03 μg/ml and 1.47 μg/ml both at 4 and 72 h, respectively. In vivo, R-PZQ was the most potent drug with worm burden reductions (WBRs) of 98.5, 75.6 and 73.3% at 125.0, 62.5 and 31.0 mg/kg, respectively. A single oral dose of 250.0 mg/kg PZQ resulted in a WBR of 99.3%. S-PZQ was highly active in vivo at 250.0 and 500.0 mg/kg with WBRs of 83.0 and 94.1%, respectively. The lowest tested dose of S-PZQ, 125.0 mg/kg, showed moderate activity (WBR of 46.7%). The calculated ED50 for R- and S-PZQ were 24.7 and 127.6 mg/kg, respectively, with a corresponding eudysmic ratio of 5.17.

Conclusion: Our data support the theory of R-PZQ driving the antischistosomal activity. Interestingly, also S-PZQ proved to possess a significant activity towards S. haematobium, particularly in vivo.

Keywords: Praziquantel, Schistosoma haematobium, In vivo, In vitro

* Correspondence: jennifer.keiser@swisstph.ch
1Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Schistosomiasis is one of the prominent neglected tropical diseases (NTDs), caused by blood-dwelling flukes of the genus *Schistosoma*. It is affecting over 230 millions of people around the world, mostly concentrated in poor, tropical and subtropical areas [1–3].

Intestinal schistosomiasis, caused by *S. mansoni* and *S. japonicum*, manifests with abdominal symptoms (e.g. blood in stool, abdominal discomfort, diarrhoea) and can lead to liver failure [4, 5], while *S. haematobium* causes urinary schistosomiasis, triggering bladder pathology, often resulting in bladder cancer [4, 6]. In addition, schistosomiasis influences the course and outcome of pregnancy and affects child’s intellectual and physiological development [7, 8].

Praziquantel (PZQ) is the only effective drug available against schistosomiasis and has been successfully in use for decades [4, 6, 9–13]. Originating from veterinary medicine and repurposed for human use, it has been thoroughly studied; however, knowledge regarding the mechanism of action is scarce [9, 11]. PZQ is a racemic compound consisting of two enantiomers, R- and S-PZQ [9, 11]. While there have been some in vitro and in vivo studies on the activity of PZQ, they mostly studied the racemic drug [14–20]. In the few studies, which explored the activity of either R- or S-PZQ, the reported findings vary. Nevertheless, most studies reported greater activity of R-PZQ over S-PZQ [21–24]. Staudt et al. [24] suggested that the main metabolite, R-trans-4-hydroxy-praziquantel (trans-4-OH-PZQ), also possesses a high antischistosomal activity on *S. mansoni*. A similar finding was reported by Xiao et al. [25] for *S. japonicum*.

It is worth highlighting that the above-mentioned studies, testing the enantiomeric activity of R- and S-PZQ, were conducted using exclusively *S. mansoni* and *S. japonicum*. *Schistosoma haematobium* remains largely unexplored, regardless of the fact that it is responsible for the largest number of infections [26]. One of the many reasons of negligence might be the life-cycle of the parasite, which is difficult to maintain in laboratory conditions [27–29]. However, drug activity should be carefully elucidated on *S. haematobium* as well, since there is evidence that the activity of drugs, e.g. PZQ, oxamnique or metrifonate, differs between species of the parasite [18, 30].

In this study, the activity of both PZQ enantiomers, R- and S-PZQ, as well as the racemic drug and the main metabolite (trans-4-OH-PZQ) was assessed on *S. haematobium*. The activity of all entities was tested in vitro on adult worms and the results were reported as IC50 values. The *S. haematobium* hamster model was used for testing different dosages of R-PZQ and S-PZQ compared with racemic PZQ in vivo. ED50 values were reported and worm burden reductions (WBRs) were compared between different treatment groups of R- and S-PZQ and the control group.

Methods

Drugs, media and animals

Pure analytes, R-, S- and trans-4-OH-PZQ were kindly supplied by Merck (Darmstadt, Germany). Racemic PZQ was purchased from Sigma Aldrich (Buchs, Switzerland). Drugs for in vitro studies were dissolved in dimethyl sulfoxide (DMSO; Fluka, Buchs, Switzerland). A mixture of 7% (vol/vol) Tween 80 and 3% ethanol (vol/vol) was used to suspend the drugs for in vivo treatment.

For cultivating adult schistosomes, standard RPMI 1640 medium (Life Technologies, Carlsbad, CA, USA) with addition of 5% heat-inactivated foetal calf serum (fCS), 100 U/ml of penicillin (Life Technologies) and 100 μg/ml of streptomycin (Life Technologies) was used.

Thirty LVG golden Syrian hamsters (male, weight approximately 150 g), infected with approximately 350 cercariae of *S. haematobium* each, were obtained from the biomedical research institute (NR-21966, Rockville, MD, USA). The animals were kept under controlled conditions (22 °C, 50% humidity, 12/24 h of light and free access to water and rodent diet) to allow development of chronic infection 3 months post-exposure.

In vitro and in vivo studies

In vitro studies

Adult worms were tested at a range of 0.01–300 μg/ml for R-PZQ and PZQ, at 0.1–30.0 μg/ml for S-PZQ and 0.1–3.0 μg/ml for trans-4-OH-PZQ. Drugs were prepared in medium using serial dilutions in flat bottom 24-well plates (BD, Falcon, Corning, NY, USA). Control wells consisted of 0.3% DMSO, which was the highest concentration of DMSO used to dissolve the drugs. Three months post-infection, *S. haematobium*-infected hamsters were euthanized with CO2 and dissected. Adult worms were collected from hepatic portal and mesenteric veins. Two to three worms, sexes equally represented, were placed per well and each concentration of the drug was tested in duplicates. Worms were incubated at 37 °C and 5% CO2 and the phenotypic changes were evaluated 1, 4, 24, 48 and 72 h post-incubation using a motility scale ranging from 3 (normal activity) to 0 (no activity, granularity present).

IC50 values were calculated with CompuSyn® software (version 1.0) from motility values at different concentrations of each drug. The linear correlation coefficient (r value) reflects the conformity of the experimental data. The eudysmic ratio was calculated using the following formula: IC50 distomer/IC50 eutomer, where R-PZQ is the eutomer and S-PZQ the distomer.
R-PZQ, 31.0 mg/kg R-PZQ, 500.0 mg/kg S-PZQ, 250.0 mg/kg S-PZQ or 125.0 mg/kg S-PZQ. 10 days post-treatment hamsters were euthanized with CO2 and dissected. Adult worms from intestinal veins were counted and sexed and the liver was inspected for live/dead worms and eggs. The control group (untreated) was dissected at the same time and the mean worm burden of treated hamsters was compared with untreated hamsters to determine the WBR. ED50 and eudysmic ratios were calculated as described above.

Statistics
Statistical tests were performed using Prism software (version 7.03, GraphPad, CA, USA). Unpaired t-test allowing for unequal variances was used to determine differences in worm burden between the control group and the treatment groups. P < 0.05 was considered to be significant.

Results
In vitro studies
In vitro IC50 and IC90 values (4 and 72 h of incubation) of racemic PZQ, pure enantiomers and trans-4-OH-PZQ obtained against adult worms of *S. haematobium* are summarised in Table 1. The IC50 of R-PZQ was 0.007 μg/ml at 4 h and 0.01 μg/ml at 72 h, while S-PZQ was 501× less active (eudysmic ratio at 4 h) yielding IC50 values of 3.51 and 3.40 μg/ml (4 and 72 h, respectively). The IC50 of PZQ was 0.03 μg/ml, which is 4.3× higher compared to R-PZQ. Trans-4-OH-PZQ revealed an IC50 of 1.47 μg/ml at 4 and 72 h, respectively.

In vivo studies
Total WBRs and female WBRs following different single oral doses of R-, S-PZQ and PZQ are presented in Table 2. For all drugs and dosages tested, a higher activity on the female worms was observed. PZQ reduced the total worm burden by 99.3% at a single dose of 250.0 mg/kg. R-PZQ showed the highest total WBR at 125.0 mg/kg (98.5%) while with a half of the dose (62.5 mg/kg) the WBR was lower (75.6%). The lowest dose of R-PZQ, 31.0 mg/kg, yielded still a high total WBR of 73.3%. S-PZQ revealed a high activity at 500.0 and 250.0 mg/kg with total WBRs of 94.1 and 83.0%. A moderate total WBR of 46.7% was observed when the hamsters were treated with 125.0 mg/kg of S-PZQ. The calculated ED50s for R- and S-PZQ were 24.7 and 127.6 mg/kg, respectively, with a corresponding eudysmic ratio of 5.17. All female and total WBRs of the different treatment groups were significantly different from the control group (P < 0.05), except for the total WBRs of lowest doses of R- and S-PZQ (31.0 mg/kg and 125.0 mg/kg, respectively), which showed not to be significantly better compared to the control group.

Discussion
With no available alternative drug, PZQ is the mainstay of schistosomiasis control [9–12]. Apart from reliance on a single drug, an additional drawback is the large dose required, resulting in a huge size of the tablet, containing a racemic mixture of PZQ [31–33]. The discussion about the activity of each enantiomer of the drug, namely R- and S-PZQ, has been on-going and therefore it is time to conclude which enantiomer is responsible for the antischistosomal activity [9, 32–34]. Moreover, development of a paediatric PZQ formulation is currently ongoing and thorough examination of in vitro and in vivo activity of PZQ and its enantiomers will not only contribute to a better understanding of the drug but also aid to select the optimal entity for the final formulation (R-PZQ or racemic PZQ) [35]. While *S. mansoni* has been thoroughly researched, *S. haematobium* remains neglected in the laboratory, despite of being responsible for a large share of the burden of schistosomiasis [26, 29]. This holds true also for drug sensitivity testing including studies on PZQ. While a few studies assessed the activity of PZQ on *S. haematobium*, all of them only evaluated the activity of racemic PZQ [18, 19, 29]. Studies on *S. haematobium* are pivotal as many antischistosomals, oxamniquine, metrifonate and PZQ have very distinct profiles on the different schistosome species [30]. To our knowledge, our study is the first to investigate the activity of both enantiomers of PZQ, at three different doses, compared to a single dose of PZQ, in vivo. Additionally, the activity of both enantiomers was compared also to the main human metabolite, trans-4-OH-PZQ, and the racemic drug, in vitro. Our results show that R-PZQ is driving the antischistosomal activity of PZQ, both in vitro and in vivo. The IC50 value of racemic PZQ was 4.3× higher compared to the enantiopure R-PZQ in vitro. In vivo results followed a similar pattern: R-PZQ at 125 mg/kg resulted in WBRs above 98%, as did a twice higher dose of PZQ, 250 mg/kg. The latter result is in the line with findings from the dose-

| Table 1 IC50 and IC90 values of PZQ, R-PZQ, S-PZQ enantiomers and trans-4-OH-PZQ against adult worms of *S. haematobium* |
|-----------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
|                 | IC50 at 4 h (μg/ml) | r-value | IC90 at 72 h (μg/ml) | r-value | IC50 at 72 h (μg/ml) | r-value | Eudysmic ratio |
| PZQ             | 0.03        | 0.978     | 0.03        | 0.965    | 0.09        | 0.978     | 501          |
| R-PZQ           | 0.007       | 0.803     | 0.01        | 0.940    | 0.03        | 0.940     |              |
| S-PZQ           | 3.51        | 0.925     | 3.40        | 0.923    | 5.98        | 0.923     |              |
| Trans-4-OH-PZQ  | 1.47        | 0.891     | 1.47        | 0.891    | 3.31        | 0.891     |              |
response relationship study with PZQ in *S. haematobium* infected hamsters conducted by Webbe & James, yielding an ED\textsubscript{50} of 118 mg/kg [18].

Strikingly, it seems that in case of *S. haematobium* in contrast to *S. mansoni* [36], also S-PZQ possesses non-negligible activity. An ED\textsubscript{50} of 127.6 mg/kg was calculated for S-PZQ, which is close to the value of the racemic drug. For comparison, *S. mansoni*-infected mice treated with 800 mg/kg S-PZQ showed only a low WBR of 19.6%. Hence, the eudysmic ratio is 64-fold lower for *S. haematobium* compared to *S. mansoni* [36]. However, it is worth highlighting that differences in the drug sensitivity between the two species might also be due to differences in the model, the hamster versus mouse model [27]. Finally, also *trans*-4-OH-PZQ revealed a 2.3 and 2.4-fold higher activity (72 and 4 h, respectively) against *S. haematobium* in vitro when compared to *S. mansoni*. A contribution of S-PZQ and *trans*-4-OH-PZQ revealed a 2.3 and 2.4-fold higher activity against *S. haematobium* in vitro when compared to *S. mansoni* [36]. However, it is worth highlighting that differences in the drug sensitivity between the two species might also be due to differences in the model, the hamster versus mouse model [27]. Finally, also *trans*-4-OH-PZQ revealed a 2.3 and 2.4-fold higher activity (72 and 4 h, respectively) against *S. haematobium* in vitro when compared to *S. mansoni*. A contribution of S-PZQ and *trans*-4-OH-PZQ to PZQ's activity could explain the higher sensitivity to PZQ of *S. haematobium* when compared to *S. mansoni* in humans [30]. In humans, *S. haematobium* are residing in the venus plexus of the bladder, getting exposed mostly to high concentrations of S-PZQ and the metabolite, as a consequence of first pass metabolism. This is in contrast to *S. mansoni*, where the adult worms are exposed to un-metabolised drug in the mesenteric veins, prior to reaching the liver.

In addition, we observed increased sensitivity of female worms compared to the males in vivo for all entities studied. For example, the lowest dose of S-PZQ achieved a female WBR of 95.6%, while the males were only mildly affected (total WBR of 46.7%). The higher activity of PZQ on female worms has been reported previously [20].

As mentioned above, due to the difficulties maintaining the *S. haematobium* life-cycle, our in vivo data are based on a single experiment and the in vitro data on duplicate experiments. While we feel our data are robust and in line with standard procedures, in order to draw a final conclusion, which PZQ enantiomer to recommend for the therapy of *S. haematobium* infections, additional experiments would be beneficial.

### Conclusion

To conclude, we observed that R-PZQ possesses the highest activity among the PZQ enantiomers and main human metabolite tested against *S. haematobium*. Surprisingly, S-PZQ- showed a high activity in vivo. Additionally, the main human metabolite displayed an activity higher than S-PZQ in vitro. In the line with the current efforts to develop a paediatric formulation, an enantioselective R-PZQ formulation might bear some risk; however, further laboratory studies as well as clinical trials, including pharmacokinetic/pharmacodynamics relationship studies, would be required to confirm our findings.

### Abbreviations

- **ED\textsubscript{50}**: Dose of the drug needed to reduce the worm burden by 50%
- **IC\textsubscript{50}**: Concentration of the drug, needed to kill 50% of the parasites
- **PZQ**: Praziquantel
- **WBR**: Worm burden reduction

### Table 2

| Worm burden reductions (WBRs) following different single oral doses of R, S-PZQ and PZQ |
|---|---|---|---|---|---|---|
| No. of hamsters cured/treated | Mean no. of alive worms ± SD | WBR (%) | Female WBR (%) | ED\textsubscript{50} (mg/kg) |
|---|---|---|---|---|
| Control | 0/4 | 2.75 ± 3.8 | 31.0 ± 9.5 | 33.8 ± 16.8 | 15.3 ± 5.2 | – | – | – |
| PZQ | | | | | | | |
| 250.0 mg/kg | 3/4 | 0.25 ± 0.5 | 0 | 0.3 ± 0.5 | 0 | 99.3 | 100 | – | – |
| 200.0 mg/kg\textsuperscript{b} | | | | | | | | | 77.2 | 118.1 |
| 150.0 mg/kg\textsuperscript{b} | | | | | | | | | 66.1 | – |
| 100.0 mg/kg\textsuperscript{b} | | | | | | | | | 39.2 | – |
| R-PZQ | | | | | | | | | – | – |
| 125.0 mg/kg | 2/4 | 0.25 ± 0.5 | 0.25 ± 0.5 | 0.5 ± 0.6 | 0 | 98.5 | 100 | 24.7\textsuperscript{a} |
| 62.5 mg/kg | 1/4 | 5.0 ± 4.7 | 3.25 ± 3.6 | 8.3 ± 8.1 | 2.3 ± 3.3 | 75.6 | 85.2 | – | – |
| 31.0 mg/kg | 0/3 | 6.7 ± 11.5 | 2.3 ± 2.3 | 9.0 ± 13.9 | 4.0 ± 6.9 | 73.3 | 73.8 | – | – |
| S-PZQ | | | | | | | | | – | – |
| 500.0 mg/kg | 3/4 | 1.25 ± 2.5 | 0.75 ± 1.5 | 2.0 ± 4.0 | 0 | 94.1 | 100 | 127.6\textsuperscript{a} | 5.17\textsuperscript{c} |
| 250.0 mg/kg | 2/4 | 4.0 ± 4.9 | 1.75 ± 2.1 | 5.8 ± 6.9 | 0 | 83.0 | 100 | – | – |
| 125.0 mg/kg | 0/3 | 7.0 ± 6.2 | 11.0 ± 6.0 | 18.0 ± 12.1 | 0.7 ± 0.6 | 46.7 | 95.6 | – | – |

\textsuperscript{a} Determined on total worm burden reductions

\textsuperscript{b} Data reported by Webbe & James [18]

\textsuperscript{c} Eudysmic ratio
Competing interests
Swiss cantonal and national regulations (permission no. 2070). The current study was approved by the local veterinary agency based on Ethics approval.

Authors’ contributions
JK and JKo designed the experiment. MV and JKo performed the experiments.

Ethics approval
The current study was approved by the local veterinary agency based on Swiss cantonal and national regulations (permission no. 2070).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 April 2017 Accepted: 13 July 2017
Published online: 01 August 2017

References
1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(5):411–25.
2. Utzinger J, Raso G, Brooker S, De Savigny D, Tanner M, Omborg N, et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology. 2009;136(3):1859–74.
3. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383(9916):2253–64.
4. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368(9541):1106–18.
5. Ismail HAHA, Hong S-T, Babiker ATEB, Hassan RMAE, Sulaiman MAZ, Jeong H- et al. Reduced susceptibility to praziquantel among naturally occurring Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol. 2004;34:527–33.
6. Ross AGP, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, et al. Schistosomiasis; African infants and preschool children: let them now be treated! Trends Parasitol. 2009;25(1):1130–184.
7. Chavasse CJ, Brown MC, Bell DR. Schistosomiasis mansoni: Activity responses in vitro to praziquantel. Z Parasitenkd. 1979;58:169–74.
8. Webbe G, James C. A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei in hamsters. Z Parasitenkd. 1977;52:169–77.
9. Xiao SH, Catto BA. The drugs we have and the drugs we need against major helminth infections. Adv Parasitol. 2010;73(10):197–230.
10. Keiser J, Utzinger J. The drugs we have and the drugs we need against major helminth infections. Curr Opin Infect Dis. 2002;15(6):659–67.
11. Olliaro P, Delgado-Romero P, Keiser J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (sacemate and R-enantiomer). J Antimicrob Chemother. 2014;69(8):633–70.
12. King CH, Dangerousfield-cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn. 2008;4(5):195–7.
13. Bustinduy AL, Wright S, Joekes EC, Kabatereine NB, Reinhard-Rupp J, King CH, et al. One hundred years of neglect in paediatric schistosomiasis. Parasitology. 2017;141:11–24.
14. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Ibrahim N, Wynn NB, et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3(8):1–7.
15. Liang Y, Coles GC, Doenhoff MJ, Southgate VR. In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol. 2001;31:1227–35.
16. Xiao SH, Catto BA, Webster LTJ. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis. 1985;151(6):1130–7.
17. Chavasse CJ, Brown MC, Bell DR. Schistosomiasis mansoni: Activity responses in vitro to praziquantel. Z Parasitenkd. 1979;58:169–74.
18. Webbe G, James C. A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei in hamsters. Z Parasitenkd. 1977;52:169–77.
19. Xiao SH, Catto BA. Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J Infect Dis. 1989;159(3):589–92.
20. Xiao SH, Chollet J, Booth M, Weiss NA, Tanner M. Therapeutic effect of praziquantel enantiomers in mice infected with Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1999;93(3):245–5.
21. Xiao SH, Catto BA. Uptake and effect of praziquantel and the major human oxidative metabolite, 4-hydroxypraziquantel, by Schistosoma japonicum. J Infect Dis. 1991;177(2):241–5.
22. Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2010;137:589–603.
23. Moore DV, Melaney HE. Comparative susceptibility of common laboratory animals to experimental infection with Schistosoma haematobium. J Parasitol. 1954;40(4):392–7.
24. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology. 2009;136:1825–35.
25. Xiao SH, Catto BA. Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J Infect Dis. 1989;159(3):589–92.
26. Xiao SH, Chollet J, Booth M, Weiss NA, Tanner M. Therapeutic effect of praziquantel enantiomers in mice infected with Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1999;93(3):245–5.
27. Staudt U, Schmahl G, Blaschke G, Melhorn H. Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on Schistosoma mansoni in vitro. Parasitol Res. 1992;78:392–7.
28. Xiao SH, You JQ, Guo HF, Catto BA. Uptake and effect of praziquantel and the major human oxidative metabolite, 4-hydroxypraziquantel, by Schistosoma japonicum. J Infect Dis. 1991;177(2):241–5.
29. Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2010;137:589–603.
30. Moore DV, Melaney HE. Comparative susceptibility of common laboratory animals to experimental infection with Schistosoma haematobium. J Parasitol. 1954;40(4):392–7.
31. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology. 2009;136:1825–35.
32. Botros S, Pica-Mattoccia L, William S, El-Lakkani N, Cioli D. Effect of praziquantel on the immature stages of Schistosoma haematobium. Int J Parasitol. 2005;35:1453–7.
33. Zwang J, Olliaro PL. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis - a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis. 2014;8(11):e3286.
34. Keiser J, Olliaro PL. Schistosomiasis: the unacknowledged impact of chronic schistosomiasis. Chronic Illn. 2008;4(5):195–7.
35. Olliaro P, Delgado-Romero P, Keiser J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (sacemate and R-enantiomer). J Antimicrob Chemother. 2014;69(8):633–70.
36. Meister I, Ingram-Sieber K, Cowan N, Todd M, Robertson MN, Meli C, et al. Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob Agents Chemother. 2014;58(9):5466–72.